Cancer biotech Kolltan Pharmaceuticals files for an $86 million IPO

Shutterstock photo

Kolltan Pharmaceuticals, an early-stage biotech developing antibodies to treat solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering. Kolltan is in Phase 1 trials for its antibody-based drugs that target receptor tyrosine kinases (RTKs).

The company licenses IP from MedImmune, which has the option to receive future payments based on the value of Kolltan's lead drug candidate. Kolltan is also in preclinical development of certain inflammatory diseases and other cancers.

Primary shareholders include Fidelity Investments (15% pre-IPO stake), KLP Enterprises (14%), Gilead Sciences (10%), Auven Therapeutics (10%) and co-founders Joseph Schlessinger (5%) and Arthur Altschul (5%).

The New Haven, CT-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol KLTN. Kolltan initially filed confidentially on August 8, 2014. Leerink Partners and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Cancer biotech Kolltan Pharmaceuticals files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?